Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, 43210, USA.
J Hematol Oncol. 2020 Jun 17;13(1):79. doi: 10.1186/s13045-020-00914-1.
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin's lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant eligible patients, or less intensive chemotherapy for the less fit (and transplant-ineligible) patients. Patients eventually relapse with a progressive clinical course. Numerous therapeutic approaches have emerged over the last few years which have significantly changed the treatment landscape of MCL. These therapies consist of targeted approaches such as BTK and BCL2 inhibitors that provide durable therapeutic responses. However, the optimum combination and sequencing of these therapies is unclear and is currently investigated in several ongoing studies. Furthermore, cellular therapies such as chimeric antigen receptor (CAR) T cells and bispecific T cell engager (BiTe) antibodies have shown impressive results and will likely shape treatment approaches in relapsed MCL, especially after failure with BTK inhibitors. Herein, we provide a comprehensive review of past and ongoing studies that will likely significantly impact our approach to MCL treatment in both the frontline (for transplant eligible and ineligible patients) as well as in the relapsed setting. We present the most up to date results from these studies as well as perspectives on future studies in MCL.
套细胞淋巴瘤（Mantle cell lymphoma，MCL）是一种罕见的 B 细胞非霍奇金淋巴瘤，具有高度异质性的临床表现和侵袭性。对于适合进行自体干细胞移植的患者，一线治疗包括强化化疗联合自体干细胞移植；对于不适合移植的患者（以及不适合进行移植的患者），则采用强度较低的化疗。患者最终会出现进行性临床病程复发。在过去几年中，出现了许多治疗方法，这些方法显著改变了 MCL 的治疗格局。这些疗法包括靶向治疗方法，如 BTK 和 BCL2 抑制剂，它们可提供持久的治疗反应。然而，这些疗法的最佳组合和顺序尚不清楚，目前正在进行多项研究。此外，细胞疗法，如嵌合抗原受体（Chimeric Antigen Receptor，CAR）T 细胞和双特异性 T 细胞衔接器（Bispecific T Cell Engager，BiTe）抗体，已显示出令人印象深刻的结果，可能会改变复发 MCL 的治疗方法，尤其是在 BTK 抑制剂治疗失败后。在此，我们全面回顾了过去和正在进行的研究，这些研究可能会显著影响我们在一线治疗（适合进行移植的和不适合进行移植的患者）以及复发治疗中对 MCL 治疗方法的选择。我们介绍了这些研究中最新的结果，并对 MCL 未来的研究进行了展望。
